Coverage
-
April 19, 2023
The Patent Trial and Appeal Board has rejected biotechnology company Streck's contention that nearly 30 claims in a Ravgen genetic testing patent are obvious or anticipated, siding with the patent owner in yet another challenge to the testing system it had used to score $272 million in infringement damages in underlying litigation.
1 other articles on this case.
View all »